MondayNightIBD Livestream Posttest/Evaluation: Better Days Ahead? Opportunities to Improve Care for Patients with IBD: A Focus on New and Emerging Therapies (ID: i802-3) Survey

Please complete this evaluation, making sure claim the appropriate amount of credit. Upon submission of a completed evaluation form, certificates will be issued via email in 1-2 weeks.

Question Title

* 1. Your patient, a 25-year-old male, presents with bloody diarrhea 5 times/day. He was diagnosed with left-sided UC with a Mayo score of 3 on endoscopy and CRP of 20 mg/L. His symptoms improve on oral corticosteroids. Based on your assessment of colectomy risk, what is the best treatment choice for this patient?

Oral and topical 5-ASA

Methotrexate

A targeted small molecule

A targeted biologic

Question Title

* 2. Your patient is a 32-year-old male with a 3-year history of moderate-to-severe UC. He presents with a moderate flare, negative stool studies, and Mayo 2 disease per flexible sigmoidoscopy. His infliximab trough level is 15, with no ATI. What changes would you make to his therapy?

Increase infliximab dose/frequency

Add azathioprine to infliximab

Switch to adalimumab

Switch MOA

Question Title

* 3. Your patient is a 45-year-old female with moderate-to-severe UC that is refractory to infliximab. She is now in clinical remission after 6 months of tofacitinib 10 mg PO BID. A repeat colonoscopy shows a Mayo 1 score. What is the next best step for this patient?

Decrease tofacitinib to 5 mg BID

Keep tofacitinib 10 mg BID

Switch to vedolizumab

Increase tofacitinib to 10 mg TID

Question Title

* 4. In the U-ACCOMPLISH induction trial of upadacitinib in moderate-to-severe UC, the clinical remission rate of upadacitinib (vs a rate of 4% in patients on placebo) was which of the following?

~10%

~20%

~30%

~40%

Question Title

* 5. In True North, significant improvement in rectal bleeding score (RBS) in patients with moderate-to-severe UC on ozanimod occurred as early as which of the following?

2 weeks

4 weeks

6 weeks

8 weeks

Question Title

* 6. What is your degree?

MD/DO

Pharmacist

Nurse

Other (please specify)

Question Title

* 7. What is your specialty?

Gastroenterology

Surgery

Dietetics

Other Specialist

Internal Medicine

Family Practice

Other (please specify)

Question Title

* 8. Please select the option that best describes your setting.

Academic medical center

Community medical center

Other (please specify)

Question Title

* 9. How many years have you been in practice?

1-10

11-20

>21

Question Title

* 10. How many patients with IBD do you manage per week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 11. After participating in this activity, how confident are you in the management of patients with UC in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Be better able to manage patients with UC through use of tools to monitor disease activity

Be better able to utilize evidence-based strategies to formulate optimal treatment regimens

Be better able to position therapies based on individual patient characteristics

Other (please explain)

Question Title

* 13. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 14. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines and/or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 15. Please rate your level of agreement by checking the appropriate rating.
Strongly agree, Agree, Neutral, Disagree, Strongly disagree

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management	Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Strongly agree	Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Agree	Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Neutral	Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Disagree	Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Strongly disagree
Analyze potential approaches for positioning new and emerging therapies for UC	Analyze potential approaches for positioning new and emerging therapies for UC Strongly agree	Analyze potential approaches for positioning new and emerging therapies for UC Agree	Analyze potential approaches for positioning new and emerging therapies for UC Neutral	Analyze potential approaches for positioning new and emerging therapies for UC Disagree	Analyze potential approaches for positioning new and emerging therapies for UC Strongly disagree
Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies	Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies Strongly agree	Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies Agree	Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies Neutral	Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies Disagree	Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies Strongly disagree

Question Title

* 16. Please rate your level of agreement by checking the appropriate rating.

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 20. Request for CME Credit:

I participated in the entire activity and claim 1.25 credits.

I participated in only part of the activity and claim 1.0 credit.

I participated in only part of the activity and claim 0.75 credit.

I participated in only part of the activity and claim 0.5 credit.

I participated in only part of the activity and claim 0.25 credit.

Question Title

* 21. To receive CME credit for completing this activity, please provide your full name, degree, and email address.

Name:

Degree:

State/Province:

Email Address

Question Title

Question Title

* 2. Your patient is a 32-year-old male with a 3-year history of moderate-to-severe UC. He presents with a moderate flare, negative stool studies, and Mayo 2 disease per flexible sigmoidoscopy. His infliximab trough level is 15, with no ATI. What changes would you make to his therapy?

Question Title

* 3. Your patient is a 45-year-old female with moderate-to-severe UC that is refractory to infliximab. She is now in clinical remission after 6 months of tofacitinib 10 mg PO BID. A repeat colonoscopy shows a Mayo 1 score. What is the next best step for this patient?

Question Title

* 4. In the U-ACCOMPLISH induction trial of upadacitinib in moderate-to-severe UC, the clinical remission rate of upadacitinib (vs a rate of 4% in patients on placebo) was which of the following?

Question Title

* 5. In True North, significant improvement in rectal bleeding score (RBS) in patients with moderate-to-severe UC on ozanimod occurred as early as which of the following?

Question Title

* 6. What is your degree?

Question Title

* 7. What is your specialty?

Question Title

* 8. Please select the option that best describes your setting.

Question Title

* 9. How many years have you been in practice?

Question Title

* 10. How many patients with IBD do you manage per week?

Question Title

* 11. After participating in this activity, how confident are you in the management of patients with UC in your practice?

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 13. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 14. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 15. Please rate your level of agreement by checking the appropriate rating.Strongly agree, Agree, Neutral, Disagree, Strongly disagreeAfter participating in today’s activity, I am now better able to:

Question Title

* 16. Please rate your level of agreement by checking the appropriate rating.

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 20. Request for CME Credit:

Question Title

* 21. To receive CME credit for completing this activity, please provide your full name, degree, and email address.

* 15. Please rate your level of agreement by checking the appropriate rating.
Strongly agree, Agree, Neutral, Disagree, Strongly disagree

After participating in today’s activity, I am now better able to: